SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Aptevo Therapeutics Inc. (APVO) (CIK 0001671584) (APVO) — Jan 29, 2026

Aptevo Therapeutics Inc. (APVO) (CIK 0001671584)
Date: Jan. 29, 2026 · CIK: 0001671584 · Accession: 0001193125-26-029443

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-293010

Date
January 29, 2026
Author
Marvin L. White
Form
CORRESP
Company
Aptevo Therapeutics Inc. (APVO) (CIK 0001671584)

Letter

January 29, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren S. Hamill Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed January 28, 2026 File No. 333-293010 Dear Ms. Hamill: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-293010) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on January 30, 2026, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704. Very truly yours, Aptevo Therapeutics Inc. By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer

CC: SoYoung Kwon, Aptevo Therapeutics Inc. Daphne Taylor, Aptevo Therapeutics Inc. Sean M. Donahue, Paul Hastings LLP

Show Raw Text
CORRESP
 1
 filename1.htm

 CORRESP

 January 29, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren S. Hamill Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed January 28, 2026 File No. 333-293010 Dear Ms. Hamill: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-293010) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on January 30, 2026, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704. Very truly yours, Aptevo Therapeutics Inc. By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer

 CC:
 SoYoung Kwon, Aptevo Therapeutics Inc. Daphne Taylor, Aptevo Therapeutics Inc. Sean M. Donahue, Paul Hastings LLP